Catena Biosciences vs athenahealth
Side-by-side comparison of AI visibility scores, market position, and capabilities
US YC W21 protein conjugation technology for homogeneous ADCs and biologics at $9.1M total ($2.35M seed May 2024 LongeVC/Caffeinated) and $750K revenue Jun 2025; MPC platform competing with Ajinomoto and Abzena for precise ADC conjugation services.
About
Catena Biosciences is a United States-based biotechnology company — backed by Y Combinator (W21) with $9.1 million in total funding including a $2.35 million seed round in May 2024 from LongeVC, CA Innovation Fund, Civilization Ventures, Pioneer Fund, Freeflow Ventures, Caffeinated Capital, and BrightEdge Capital, plus NIH SBIR grants — developing next-generation protein conjugation technology that enables the rapid, selective attachment of functional payloads (drugs, labels, polymers, other proteins) to therapeutic proteins using natural amino acids as conjugation handles, generating $750,000 in annual revenue as of June 2025 and serving pharmaceutical companies and researchers developing antibody-drug conjugates (ADCs), bispecific antibodies, vaccine adjuvants, and next-generation protein therapeutics for autoimmune disorders, oncology, and infectious disease.
$1.7B annual revenue; 160K+ providers, 117M patients; 18.15% EHR market share; 6,713+ companies using 2025; acquired by Bain Capital & Hellman & Friedman Nov 2021 at $17B; AI interoperability 2025
About
athenahealth is a cloud-based electronic health records (EHR), medical billing, and practice management company founded in 1997 and headquartered in Watertown, Massachusetts. The company was built on the principle that healthcare administration should be managed as a service — with athenahealth absorbing the complexity of payer rule updates, regulatory compliance, and billing workflows so that physicians and clinical staff can focus entirely on patient care. Its cloud-native architecture, deployed before most EHR competitors moved to the cloud, remains a core technical differentiator.\n\nathenahealth's platform — athenaOne — integrates EHR, revenue cycle management, patient engagement, and care coordination in a single system used by over 160,000 providers across 117 million patient records. The company serves ambulatory practices ranging from solo physicians to large health systems and medical groups. Its continuously updated rules engine processes millions of payer transactions daily, enabling higher clean claim rates and faster reimbursement compared to on-premise EHR alternatives. athenahealth holds an 18.15% share of the US ambulatory EHR market.\n\nathenahealth is currently owned by a private equity consortium of Bain Capital and Hellman & Friedman, which acquired the company in 2019 for $5.7 billion. Annual revenue stands at approximately $1.7 billion. The company competes with Epic, eClinicalWorks, and Oracle Health in the ambulatory EHR market. Its managed-service model, shared payer network data, and cloud-native infrastructure continue to make it a compelling choice for ambulatory providers who prioritize revenue cycle performance and reduced administrative burden.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.